Roles of the Polycomb group proteins in stem cells and cancer von Richly, H, Aloia, L, Di Croce, L

Volltext

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study von Strumberg, D, Scheulen, M E, Schultheis, B, Richly, H, Frost, A, Büchert, M, Christensen, O, Jeffers, M, Heinig, R, Boix, O, Mross, K

Volltext

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticanc... von Bergmann, L, Maute, L, Heil, G, Rüssel, J, Weidmann, E, Köberle, D, Fuxius, S, Weigang-Köhler, K, Aulitzky, W E, Wörmann, B, Hartung, G, Moritz, B, Edler, L, Burkholder, I, Scheulen, M E, Richly, H

Volltext

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer von Bergmann, L, Maute, L, Heil, G, Rüssel, J, Weidmann, E, Köberle, D, Fuxius, S, Weigang-Köhler, K, Aulitzky, W.E, Wörmann, B, Hartung, G, Moritz, B, Edler, L, Burkholder, I, Scheulen, M.E, Richly, H

Volltext

ZRF1 controls oncogene-induced senescence through the INK4-ARF locus von Ribeiro, J D, Morey, L, Mas, A, Gutierrez, A, Luis, N M, Mejetta, S, Richly, H, Benitah, S A, Keyes, W M, Di Croce, L

Volltext

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial von Richly, H, Schultheis, B, Adamietz, I.A, Kupsch, P, Grubert, M, Hilger, R.A, Ludwig, M, Brendel, E, Christensen, O, Strumberg, D

Volltext

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors von Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., Strumberg, D.

Volltext

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer von Mayer, Erica L., Scheulen, M. E., Beckman, J., Richly, H., Duarte, A., Cotreau, M. M., Strahs, A. L., Agarwal, S., Steelman, L., Winer, E. P., Dickler, M. N.

Volltext

PP 51 Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel) von Scheulen, M.E, Nokay, B, Richly, H, Hoffmann, A-C, Kalkmann, J, Stattaus, J, Bornfeld, N, Schuler, M.H, Hense, J

Volltext

A Series of Ubiquitin Binding Factors Connects CDC48/p97 to Substrate Multiubiquitylation and Proteasomal Targeting von Richly, Holger, Rape, Michael, Braun, Sigurd, Rumpf, Sebastian, Hoege, Carsten, Jentsch, Stefan

Volltext

44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial von Ponz-Sarvise, M., Gromke, T., Magdalena, A. Landa, Richly, H., Liffers, S-T., Kasper-Virchow, S., Garonce-Hediger, R., Alvarez, E. Castanon, Paredes, L. Ceniceros, Ortega, A. Chopitea, Siveke, J.T.

Volltext

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid... von STRUMBERG, Dirk, RICHLY, Heike, SCHWARTZ, Brian, AWADA, Ahmad, VOIGTMANN, Rudolf, SCHEULEN, Max E, SEEBER, Siegfried, HILGER, Ralf A, SCHLEUCHER, Norbert, KORFEE, Sonke, TEWES, Mitra, FAGHIH, Markus, BRENDEL, Erich, VOLIOTIS, Dimitris, HAASE, Claus G

Volltext

Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone von Rape, M, Hoppe, T, Gorr, I, Kalocay, M, Richly, H, Jentsch, S

Volltext

Shp1 and Ubx2 are adaptors of Cdc48 involved in ubiquitin-dependent protein degradation von Schuberth, Christian, Richly, Holger, Rumpf, Sebastian, Buchberger, Alexander

Volltext

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors von Mross, K., Richly, H., Schleucher, N., Korfee, S., Tewes, M., Scheulen, M. E., Seeber, S., Beinert, T., Schweigert, M., Sauer, U., Unger, C., Behringer, D., Brendel, E., Haase, C. G., Voliotis, D., Strumberg, D.

Volltext

Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels von Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B.C., Sayehli, C.M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P., Joerger, M.

Volltext

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours von Scheulen, M, Mross, K, Richly, H, Nokay, B, Frost, A, Scharr, D, Lee, K.H, Saunders, O, Hilbert, J, Fietz, O

Volltext

50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors von Richly, H, Rubin, S.D, Madi, A, Jeffels, M, Nokay, B, Gibson, D, Weller, S, Scheulen, M.E, Plummer, R

Volltext

A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study von Joerger, M., Soo, R.A., Cho, B.C., Navarro, A., Sayehli, C.M., Richly, H., Tai, D., Kim, D-W., Wolf, J., Cassier, P., Bender, S., Ellinghaus, P., Ince, S., Rajagopalan, P., Ocker, M., Schuler, M.

Volltext

47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study von Weihrauch, M.R, Richly, H, von Bergwelt-Baildon, M.S, Hacker, U, Shimabukuro-Vornhagen, A, Nokay, B, Tschaika, M, Schmidt, M, Wittig, B, Scheulen, M.E

Volltext